10 31 25 (Topiramate 25 mg)
Pill with imprint 10 31 25 is White, Round and has been identified as Topiramate 25 mg. It is supplied by Torrent Pharmaceuticals.
Topiramate is used in the treatment of epilepsy; lennox-gastaut syndrome; seizure prevention; migraine prevention; seizures and belongs to the drug class carbonic anhydrase inhibitor anticonvulsants. There is positive evidence of human fetal risk during pregnancy. Topiramate 25 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for 10 31 25

Topiramate
- Imprint
- 10 31 25
- Strength
- 25 mg
- Color
- White
- Size
- 5.00 mm
- Shape
- Round
- Availability
- Prescription only
- Drug Class
- Carbonic anhydrase inhibitor anticonvulsants
- Pregnancy Category
- D - Positive evidence of risk
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Torrent Pharmaceuticals
- Inactive Ingredients
-
silicon dioxide colloidal, hypromelloses, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol 400, pregelatinized corn starch, sodium starch glycolate type A potato, magnesium silicate, titanium dioxide
Note: Inactive ingredients may vary.
Labelers / Repackagers
NDC Code | Labeler / Repackager |
---|---|
13668-0031 | Torrent Pharmaceuticals Limited |
43063-0094 | PDRX Pharmaceuticals Inc. (repackager) |
Related Images for "10 31 25"
More about topiramate
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Patient Tips
- Drug Images
- Drug Interactions
- Compare Alternatives
- Support Group
- Pricing & Coupons
- En Español
- 1109 Reviews
- Drug class: carbonic anhydrase inhibitor anticonvulsants
- FDA Alerts (3)
Consumer resources
- Topiramate
- Topiramate (Advanced Reading)
- Topiramate Extended-Release Capsules
- Topiramate Extended-Release Sprinkle Capsules
- Topiramate Tablets
- Topiramate Sprinkle Capsules
Other brands: Topamax, Trokendi XR, Topamax Sprinkle, Qudexy XR, Topiragen
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.